Bayer Schering Pharma

• Sales in 2008: EUR 10.704 billion

• Headquarter: Berlin (Germany)

The 2006 acquisition of Schering was the largest purchase in Bayer’s history. The takeover led to the formation of Bayer Schering Pharma, a powerful, leading division that ranks among the top ten pharmaceutical specialists in the world and holds a strong position in Biologicals.

Bayer Schering Pharma is concentrating on four strategic business units: Diagnostic Imaging, General Medicine, Specialty Medicine, and Women’s Healthcare.

Bayer Schering Pharma is concentrating on well-established brands.

Its highest-selling products include:

• YAZ®/ Yasmin®/ Yasminelle® (hormonal contraceptive)
• Betaferon®/Betaseron® (multiple sclerosis)  
• Kogenate® (hemophilia)
• Adalat® (hypertension)
• Avalox®/Avelox® (respiratory tract infections)
• Nexavar® (cancer)
• Mirena® (hormonal contraceptive)
• Levitra® (erectile dysfunction)
• Cipro®/ Ciprobay® (infectious diseases, especially of the urinary tract)
• Glucobay® (diabetes) 

• Health advice on Bayer Schering Pharma topics
• Bayer Schering Pharma research activities
• Internet portal of the Bayer Schering Pharma